Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

63results about How to "Reduce the size of cerebral infarction" patented technology

Preparation method and application of pedunculoside

This invention relates to ilexin, drug combination of ilexin and its extraction method, which is used to treat CHD, angina pectoris, stroke, cardiac infarction and other cerebral vascular diseases. It uses ethanol for extraction, adds water into the extract, centrifuges to get the sediments and supernatant. Sediments are added 50-95% ethanol for extraction and filtration, the liquid is concentrated, placed and filtrated, and the sediments are dried to get a part of total saponin, the saponin is crystallized by ethanol to get a part of ilexin. The supernatant is enriched and centrifuged for the sediments, which is washed with appropriate water and crystallized by ethanol after dried to get another part of ilxin. Two parts of ilxin are put together and recrystallized for several times to get the pure ilxin, which content can be more than 98.0%.
Owner:李超生 +1

Medication for anti ischemia on heart and brain, as well as preventing and treating fatty liver

A Chinese medicine for preventing and treating cardiac and cerebral ischemia and fatty liver is prepared from arasaponin extracted from notoginseng, the ginkgolide and ginkgetin extracted from ginkgo leaf, and the polydanshinolic acid and danshinon extracted from red sage root.
Owner:朱书和

Compound for treating cerebral infarction and preparation method of compound

The invention relates to a compound for treating cerebral infarction. The invention further relates to a preparation method of the compound and an application of the compound for preparing a drug for treating the cerebral infarction. The compound can significantly reduce thrombosis generated after rat vein ligation, and can obviously reduce an area of the cerebral infarction of a rat with middle cerebral artery occlusion. Therefore, the compound can prevent the thrombosis, can facilitate thrombolysis, and can be used in prevention and treatment of the cerebral infarction such as cerebral thrombosis and cerebral embolism.
Owner:牡丹江医学院附属红旗医院

Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same

The invention belongs to the medical technical field and discloses a drug combination for the cardiovascular disease and the preparation method of the drug combination. The drug combination contains the pharmacodynamic components of the raw materials of drugs of danshen root, Szechwan lovage rhizome, panax notoginseng, milkvetch root and storax. In order to achieve a better curative effect, a leech, tonka beans and peach nuts can also be added into the drug combination; in order to further improve the curative effect, rosewood, axillary choerospondias fruit and earthworms can be added into the drug combination. The drug combination of the invention has the efficacies of promoting the circulation of qi to induce resuscitation, activating blood circulation for removing blood stasis, dredging channels for alleviating pain etc. and is used for preparing the drugs for remedying the cerebral infarction convalescence of the coronary heart disease, the angina pectoris or the arteriosclerosis, the syndrome of which belong to the qi stagnation and blood stasis with the symptoms of chest pain, oppression in the chest, shortness of breath, heart throb, inefficaciousness of limbs, inarticulacy etc. The drug combination of the invention can be made into any preparation type, which is acceptable in the clinic and the pharmacy, and the oral preparation is preferential.
Owner:吴浩山

Method for treating cerebral ischemia reperfusion injury by using dental pulp stem cell exosome

The invention relates to the technical field of dental pulp stem and fine treatment, in particular to a method for treating cerebral ischemia reperfusion injury by using a dental pulp stem cell exosome. The method comprises the steps: extraction of exosomes from dental pulp stem cells, extraction of third molars without dental caries and periodontal lesions from healthy volunteers at age of 18 to 30 years-disinfection of tooth surface with 75% alcohol-removal of dental pulp from dental drill-cutting into pieces of 1 mm3-flushing three times with PBS containing 2.5% antibiotic-placement of pulp tissue in 1.5 ml EP tube with digestion of 3 mg/ml type I collagenase-placement in dispase of 4 mg/mL for 30 minutes at 37 DEG C-cell resuspension- and culturing in a 5% CO2 incubator at 37 DEG C; brain tissue is an organ most sensitive to ischemia and hypoxia of the body, irreversible brain injury occurs after blood flow supply is interrupted for several minutes, animal experiments find that the exosome from the dental pulp stem cells can reduce the cerebral infarction area after cerebral ischemia-reperfusion injury of a mouse, and a key technology is provided for clinical application of the dental pulp stem cell exosome in treatment of cerebral ischemia-reperfusion injury.
Owner:优牙生物科技(上海)有限公司

Leonurine borneol derivative as well as preparation method and application thereof

The invention provides a leonurine borneol derivative, the leonurine borneol derivative is a compound shown as B1 or B2 or a stereoisomer or a pharmaceutically acceptable salt form thereof, and the invention also provides a preparation method of the derivative and an application of the derivative in a medicine for preventing and treating nervous system diseases or cardiovascular and cerebrovascular diseases. The leonurine borneol derivative provided by the invention has a remarkable neuroprotective effect, can repair nerve cell injury, and also can play a role in obviously reducing lipid, so that the leonurine borneol derivative has remarkable pharmacological activity for treating and preventing nervous system and cardiovascular and cerebrovascular diseases, has important significance for developing novel drugs for preventing or treating nervous system and cardiovascular and cerebrovascular diseases.
Owner:WEIFANG UNIV OF SCI & TECH

Application of mitiglinide in preparation of medicine for treating cerebral arterial thrombosis

The invention provides an application of mitiglinide (MGN) in preparation of a medicine for treating the cerebral arterial thrombosis. An experiment shows that under the condition that the dosage of blood sugar is not reduced, the MGN can obviously improve the neurological disorder of a mice model or a rat model suffering from the cerebral arterial thrombosis and reduce the volume of the cerebral infarction; and the MGN inhibits the reduction of the survival rate of SH-SY5Y cells of a neuron cell strain caused by the oxygen-glucose deprivation (OGD), so that release of lactic dehydrogenase (LDH) is reduced, and the neuronal apoptosis caused by the OGD is improved. A result shows that the MGN has pharmacological effects of treating the cerebral arterial thrombosis and reducing the neuron damage caused by the OGD; and the treatment effect is bidirectional. The invention aims to prepare the medicine for treating the cerebral arterial thrombosis by taking the MGN as an active component.
Owner:NANJING MEDICAL UNIV

A kind of leech polypeptide with antithrombotic and brain nerve cell protection and its application

ActiveCN110437307BGood plasma stabilityLow toxicityPeptide/protein ingredientsPeptidesDiseaseVon Willebrand factor
The invention discloses hirudo polypeptide with functions of antithrombus and brain nerve cell protection and application of the hirudo polypeptide, and relates to the fields of traditional Chinese medicine, natural medicine and health care products. The structure of the hirudo polypeptide is presented as a formula I, human umbilical vein endothelial cell expressing vascular hemophilia factor (vWF) and a plasminogen activator inhibitor-1(PAI-1) can be significantly lowered at the low concentration of the hirudo polypeptide, the survival rate of nerve cells after oxygen and glucose deprivationis increased, platelet aggregation in vitro is inhibited, the plasma recalcification time is prolonged, formation of thrombi in vivo is reduced, neurobehavior after cerebral infarction of a rat is improved, encephaledema is relieved, the area of cerebral infarction is reduced, the toxicity is low, good application prospects are achieved, and the hirudo polypeptide can be used for preparing medicine or health care products for treating or adjuvant therapy of cardiovascular and cerebrovascular diseases such as atherosclerosis, thrombi and cerebral post-stroke nerve function deficit. The formulaI is NH2-Leu-D-Leu-Ser-Gly-Val-R whitmantide A: R=D-Leu-Gly-COOHwhitmantide B: R=D-Leu-Gly-Gly-COOH whitmantide C: R=COOH.
Owner:JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products